Loading chart data...
Amylyx Pharmaceuticals shares exploded higher today following the release of positive topline results from the pivotal Phase 3 LUCIDITY trial, which showed that the drug avexitide reduced the rate of clinically significant hypoglycemic events by 55% in patients with post-bariatric hypoglycemia. The clinical success prompted analyst upgrades to a strong buy rating, reflecting optimism regarding the potential for the company to deliver a first-in-class treatment for the condition. However, the stock's momentum was tempered late in the session by the company's announcement of a proposed 350 million dollar public offering of common stock.
That explains the day. Whether AMLX is a business worth owning is a longer question. Koyfin has the ten-year financials, margin history and valuation to answer it — 20% off for WhyTheMove readers.
No significant catalyst events detected.
AMLX moved for a reason you can read above. What the company earns, owns and guides to is a separate record. Koyfin is where the question moves from today's move to the business behind it — analyst estimates, filings and earnings transcripts.
Research AMLX in Koyfin →7-day full-access trial · 20% off paid plans